This is an institutional, monocentric, open-label, phase II study of oral metronomic Vinorelbine plus Capecitabine and Cyclophosphamide (VEX) in patients with advanced breast cancer .~Patients will receive the combination regimen as follow:~Cyclophosphamide 50 mg daily Capecitabine 500 mg, thrice daily Vinorelbine 40 mg orally thrice a week~Four independent cohorts of patients will be evaluated in the study:~Untreated (naïve) patients with endocrine responsive disease~Pretreated patients with endocrine responsive disease~Untreated (naïve) patients with triple negative disease~Pretreated patients with triple negative disease Combination will be administered until disease progression or unacceptable toxicity.~The primary endpoint will be to assess the Time to progression (TTP) of VEX combination in the four different cohorts
This is a phase II study assessing the activity and safety of metronomic chemotherapy with cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four different cohort of patients:~Untreated (naïve) patients with endocrine responsive disease~Pretreated patients with endocrine responsive disease~Untreated (naïve) patients with triple negative disease~Pretreated patients with triple negative disease The primary endpoint will be the progression-free survival